01361nam 2200373Ia 450 991069883860332120090521110736.0(CKB)5470000002397481(OCoLC)334535486(EXLCZ)99547000000239748120090521d2004 ua 0enguran|||||||||txtrdacontentcrdamediacrrdacarrierGuidance for industry[electronic resource] criteria for safety and efficacy evaluation of oxygen therapeutics as red blood cell substitutesRockville, MD :U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,[2004]i, 17 pages digital, PDF fileTitle from PDF title page (viewed on May 21, 2009)."Draft guidance.""October 2004".Guidance for industry Oxygen therapyUnited StatesEvaluationErythrocytesTransfusionUnited StatesOxygen therapyEvaluation.ErythrocytesTransfusionCenter for Biologics Evaluation and Research (U.S.)GPOGPOBOOK9910698838603321Guidance for industry3434577UNINA